<DOC>
	<DOCNO>NCT02656290</DOCNO>
	<brief_summary>The objective trial ass safety effectiveness Edwards Pericardial Aortic Bioprosthesis Model 11000A pulmonary position subject five year old require replacement native prosthetic pulmonary valve .</brief_summary>
	<brief_title>COMMENCE Pulmonary : Clinical Evaluation Edwards Pericardial Aortic Bioprosthesis ( Model 11000A ) Pulmonary Valve Replacement</brief_title>
	<detailed_description>This prospective , Non-Randomized , Single Arm , Multicenter study . Up one hundred ( 100 ) pulmonary valve replacement ( PVR ) subject ten ( 10 ) clinical site enrol assess safety effectiveness Edwards Peri-cardial Aortic Bioprosthesis Model 11000A pulmonary position . The trial include male female subject five year older require pulmonary valve replacement native prosthetic valve . Subjects follow assessed implant 5 year .</detailed_description>
	<mesh_term>Pulmonary Valve Insufficiency</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>1 . Has pulmonary valve disease require pulmonary valve replacement native prosthetic valve 2 . Is great equal 5 year age 3 . Subject and/or subject 's legal representative provide write informed consent Exclusion criterion : A subject meeting follow criterion shall exclude : 1 . Requires valveinconduit procedure 2 . Requires emergency surgery 3 . Has acute myocardial infarction ( MI ) within 30 day prior screen date 4 . Has MRI CT scan confirm stroke , cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within 6 month ( 180 day ) prior screen date 5 . Has hemodynamic respiratory instability require inotropic support , mechanical circulatory support , mechanical ventilation within 30 day prior screen date 6 . Has active endocarditis/myocarditis endocarditis/myocarditis within 3 month prior screen date 7 . Has renal insufficiency determine creatinine ( SCr ) level ~ 2.5 mg/dL within 60 day prior screen visit endstage renal disease 8 . Has document leukopenia ( WBC &lt; 3.5x 103/IlL ) , acute anemia ( Hgb &lt; 10.0 g/dL 6 mmol/L ) , thrombocytopenia ( platelet count &lt; 50xl03/IlL ) accompany history bleed diathesis coagulopathy within 60 day prior screen date 9 . Diagnosed abnormal calcium metabolism and/or hyperparathyroidism 10 . Echocardiographic evidence intracardiac mass , thrombus , vegetation 11 . RVOT aneurysm unless treat pulmonary valve replacement surgery 12 . Has prior organ transplant currently organ transplant candidate 13 . Was previously implant study trial device 14 . Previously implant aortic , mitral , tricuspid bioprosthetic valve , mechanical valve 15 . Need concomitant replacement aortic , mitral tricuspid valve annuloplasty ring remain situ 16 . Has presence noncardiac disease limit life expectancy le 12 month 17 . Is Currently recently participate ( within 6 week ) another investigational drug device trial 18 . Positive urine serum pregnancy test female subject childbearing potential and/or nursing mother 19 . Has leave ventricular ejection fraction â‰¤20 % validate diagnostic procedure prior screen date planning become pregnant participation trial 20 . Currently incarcerate unable give voluntary inform consent 21 . Documented history substance ( drug alcohol ) abuse within last 5 year prior screen date IntraOp Exclusion Criterion : 22 . Significant injury heart upon entry</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>